Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 713-717

  Chen, Yuh Min ^a,b,d   Fan, Wen Chien ^e   Tseng, Pei Chun ^a   Tsai, Chun Ming ^a,c   Chou, The Ying ^b   Wu, Chieh Hung ^a   Chou, Kun Ta ^a   Lee, Yu Chin ^a   Perng, Reury Perng ^a   Whang Peng, Jacqueline ^d  

^a Chest Department   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e Chutung Veterans General Hospital   (Taiwan)

Author keywords

Adenocarcinoma; Epidermal growth factor receptor; Erlotinib; Targeted therapy

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER TISSUE; DNA SEQUENCE; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL;

EID: 84862939146     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.534     Document Type: Article

References (14)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J and Johnson DH: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non&2011;small-cell lung cancer. J Clin Oncol 27: 6251-6266, 2009
3. Shepherd FA, Pereira JR, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
4. Mok TS, Wu YL, Thongpraser t S, et al: Gefitinib or carboplatin&2011;paclitaxel in pulmonary adenocarcinoma. NewEngJMed361: 947-957, 2009.
5. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. NEngl J Med 362: 2380-2388, 2010.
6. Zhou C, Wu YL, Chen G, et al: Efficacy results from the randomized phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 21c (Suppl 8): LBA13, 2010.
7. Rosell R, Gervais R, Vergnenegre A, et al: Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. Proc Am Soc Clin Oncl A7503, 2011.
8. Pao W and Ladanyi M: Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13: 4954-4955, 2007.
9. Kimura H, Kasahara K, Kawaishi M et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12: 3915-3921, 2006.
10. Mack PC, Holland WS, Burich RA, et al: EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. JThorac Oncol 4: 1466-1472, 2009.
11. Pathak AK, Bhutani M, Kumar S, Mohan A and Guleria R: Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chemistry 52: 1833-1842, 2006.
12. Tanaka T, Nagai Y, Miyazawa H, et al: Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 98: 246-252, 2007.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
14. Pao W and Ladanyi M: Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. ClinCancer Res 13: 4954-4955, 2007.